drugset / Trial / NCT04208958

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

NCT04208958

NaSingle-groupOpen-labelTreatment

Summary

This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer

Timeline

Start
2020-01-23
Primary completion
2021-08-26
Completion
2023-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject VE800 Other / unclassified Oral
Background Nivolumab Monoclonal antibody
Background Vancomycin Other / unclassified Oral